COVID-19 may increase the risk of blot cots in pregnant women, or in those taking estrogen with birth control or hormone replacement therapy, say scientists who call for the development of innovative animal experiment models to further study this association
According to the researchers, including those from the Tufts University School of Medicine in the US, one of the many complications of COVID-19 is the formation of blood clots in previously healthy people.
Female hormone estrogen also increases the chance of blood clots during pregnancy, and in women taking birth control pills or hormone replacement therapy. If infected with COVID-19, the risk of blood clotting could be even higher, and these women may need to undergo anticoagulation therapy, or discontinue their estrogen medicines.
The scientists believe further research is needed to understand the effects of the novel coronavirus on coagulation, answering if the virus aggravates the risk of blood clots and strokes associated with oral contraceptive pills, other estrogen therapies, and pregnancy-associated risks.
"During this pandemic, we need additional research to determine if women who become infected with the coronavirus during pregnancy should receive anticoagulation therapy, or if women taking birth control pills or hormone replacement therapy should discontinue them," said Daniel Spratt, the study''s corresponding author from Tufts University School of Medicine in Boston, US.
All required precautionary measures should be taken before hand is the only way to cross over the situation; likewise following home quarantine and be self isolated if any infected person is nearby or in house and pregnant women especially should have regular immunity boosting diet to thrive the disease and virus.Regular check-up and monitoring should be done if pregnant women feels any discomfort.
According to the researchers, collaborative efforts between clinicians and basic researchers, and between endocrinologists and hematologists are necessary to understand the interactions between the novel coronavirus and pregnancy or estrogen therapy that could guide clinical management.
Source:The Hans India